Hidradenitis Suppurativa Wound Care

Status Active, not recruiting

Clinical Trial Summary

The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.

Clinical Trial Description

Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory disease most frequently affecting the axilla, groin, and inframammary regions. Symptoms include nodules, abscesses, sinus tract formation, malodorous drainage, and scarring. These symptoms interfere with everyday activities, which can lead to social embarrassment and isolation. Patients with HS suffer psychological effects, such as increased levels of anxiety, depression, and loneliness, which impair quality of life. Patients suffer with the burden of at home wound care for recurrent, draining nodules. Persistent lesions affect patients' lives by limiting their daily activities. Currently, patients are instructed to use gauze and tape to cover draining wounds, but this can be insufficient and difficult due to the nature and location of lesions associated with HS. Patients suffer with caring for their wounds, which can lead to frustration. Providing patients with a standard wound care regimen to take home can improve patients' quality of life and control of their disease. General recommendations for wound care in HS patients are limited. Improvements in the standard of care for wound management in HS are needed to aid patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04354012
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 4, 2021
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed	`NCT02896920` - Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
Completed	`NCT01468233` - Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa	Phase 3
Completed	`NCT01468207` - Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa	Phase 3
Completed	`NCT03894956` - Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
Completed	`NCT03001115` - Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
Not yet recruiting	`NCT05723757` - Autophagy Dysfunction in Hidradenitis Suppurativa	N/A
Completed	`NCT02808975` - Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically	Phase 4
Completed	`NCT04430855` - A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms	Phase 2
Recruiting	`NCT06212999` - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 3
Completed	`NCT03487276` - Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 2
Recruiting	`NCT05620836` - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 3
Not yet recruiting	`NCT05735925` - The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis	N/A
Recruiting	`NCT05620823` - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 3
Recruiting	`NCT06241573` - A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab	Phase 2/Phase 3
Available	`NCT05583604` - Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)